Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of “Moderate Buy” from Analysts

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $63.25.

Several equities research analysts have recently weighed in on SUPN shares. Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $40.00 to $65.00 in a report on Thursday, October 9th. Bank of America started coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They set a “buy” rating and a $65.00 price objective on the stock. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. TD Cowen boosted their target price on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Tuesday.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 59,900 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the completion of the transaction, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. The trade was a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Frank Mottola sold 5,000 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $45.87, for a total transaction of $229,350.00. Following the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $710,801.52. This represents a 24.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 183,135 shares of company stock valued at $8,773,587. 8.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SUPN. Rubric Capital Management LP bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $21,908,000. Woodline Partners LP lifted its stake in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares during the period. Armistice Capital LLC boosted its holdings in Supernus Pharmaceuticals by 7.4% in the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock valued at $170,169,000 after acquiring an additional 360,000 shares during the last quarter. Bank of America Corp DE increased its position in Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after purchasing an additional 338,584 shares during the period. Finally, UBS Group AG raised its holdings in Supernus Pharmaceuticals by 137.6% during the 3rd quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock worth $25,812,000 after purchasing an additional 312,775 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 0.4%

SUPN stock opened at $46.26 on Friday. The firm has a market cap of $2.65 billion, a P/E ratio of 40.23 and a beta of 0.75. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $57.65. The business’s 50 day moving average is $48.59 and its 200-day moving average is $40.73.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a net margin of 9.70% and a return on equity of 14.22%. The company had revenue of $170.00 million during the quarter, compared to the consensus estimate of $175.82 million. During the same quarter last year, the company earned $0.69 earnings per share. The business’s revenue was up 9.3% on a year-over-year basis. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Supernus Pharmaceuticals will post 2.38 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.